LOS ANGELES (Reuters) – Two powerful and innovative cholesterol drugs likely to be approved this summer both target the same protein and have been shown to sharply lower LDL in high-risk patients. But there is at least one significant difference between the two offerings: the dosages in which they will be sold.
Insight: Fight over hot new cholesterol drugs may be won in milligrams
No comments:
Post a Comment